Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial

IMPORTANCE: The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival. The Three or Six Colon Adjuvant (TOSCA) trial compared 3 months with 6 months...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Petrelli, Fausto, Labianca, Roberto, Zaniboni, Alberto, Lonardi, Sara, Galli, Fabio, Rulli, Eliana, Rosati, Gerardo, Corallo, Salvatore, Ronzoni, Monica, Cardellino, Giovanni Gerardo, Mattioli, Rodolfo, Mambrini, Andrea, Ciuffreda, Libero, Banzi, Maria, Pusceddu, Valeria, Maiello, Evaristo, Zampino, Maria, Zagonel, Vittorina, Marchetti, Paolo, Corsi, Domenico, Rimassa, Lorenza, Cinieri, Saverio, Sobrero, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7042800/
https://ncbi.nlm.nih.gov/pubmed/32053133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.6486
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados